{
    "clinical_study": {
        "@rank": "35253", 
        "arm_group": [
            {
                "arm_group_label": "Vedolizumab 300mg", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous  Vedolizumab (300 mg) administered at Weeks 0, 2, and 6 and every 8 weeks thereafter"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vedolizumab Placebo. Intravenous infusion at Weeks 0, 2, and 6 and every 8 weeks thereafter"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,\n      parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002\n      (Vedolizumab) in induction and maintenance therapy in Japanese patients with  moderately or\n      severely active  Crohn's disease."
        }, 
        "brief_title": "Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,\n      parallel-group study to examine the efficacy, safety, and pharmacokinetics of intravenous\n      Vedolizumab (300 mg) infusion in induction and maintenance therapy in Japanese patients with\n      moderately or severely active Crohn's disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Patients aged 15 to 80 years (inclusive) at the time of consent 2. Patients with a\n             diagnosis of small-intestinal, large-intestinal,or small-/large-intestinal Crohn's\n             disease established based on the Revised Diagnostic Criteria for Crohn's disease\n             issued by Research Group for Intractable Inflammatory Bowel Disease Designated as\n             Specified Disease by the Ministry of Health, Labor and Welfare of Japan (2012) at\n             least 3 months before the start of administration of study drug 3. Patients  with\n             baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450(inclusive) and\n             meeting at least one of the followings:\n\n               -  C-reactive protein (CRP)  at screening test is above 0.30 mg/dL\n\n               -  Patients with irregular or semicircular ulcers or multiple aphthae (10 or more)\n                  observed over an extensive area of  the small or large intestine on  endoscopy\n                  or  imaging test within the 4 months before  the start of administration of\n                  study drugs\n\n               -  Patients with longitudinal ulcers or a cobblestone appearance observed in the\n                  small or large intestine on endoscopy or  imaging test within 4 months before\n                  the start of administration of study drugs 4. In case of the patients who meet\n                  any of the following criteria; patients with \u2265 8-year history of extensive or\n                  limited colitis, patients aged \u2265 50 years, or patients with a first-degree\n                  family history of colon cancer, those whom the complication of colon cancer or\n                  dysplasia was ruled out by total colonoscopy at the start of study drug\n                  administration (Or the results from total colonoscopy performed within 1 year\n                  before giving consent are available) 5. Patients meeting the criteria for\n                  treatment failure below with at least one of the following agents received\n                  within previous 5 year period before giving consent Corticosteroids\n\n               -  Resistance\n\n               -  Dependence\n\n               -  Intolerance Immunomodulators (azathioprine, 6-mercaptopurine or methotrexate)\n\n               -  Refractory\n\n               -  Intolerance Anti-TNF\u03b1 antibodies\n\n               -  Inadequate response\n\n               -  Loss of response\n\n               -  Intolerance\n\n        Exclusion Criteria:\n\n          -  Patients with an evidence of or suspected abdominal abscess 2. Patients with a\n             history of subtotal or total colectomy 3. Patients who have had a resection of the\n             small intestine in at least 3 locations or have a diagnosis of short bowel syndrome\n             4. Patients with ileostomy,colostomy,or  internal fistula, or severe intestinal\n             stenosis 5. Patients who started 5-aminosalicylic acid oral drug or probiotics\n             treatment, antimicrobials to treat Crohn's disease, or 30 mg/day or less of oral\n             corticosteroids within 13 days before initiation of study drug administration. If\n             these drugs were used within 14 days before initiation of study drug administration,\n             the dosage must have been changed or their use discontinued within 13 days before the\n             initiation of study drug administration 6. Patients who have received\n             5-aminosalicylic acid or corticosteroid enemas/suppositories, intravenous\n             corticosteroid injections, or more than 30 mg/day of oral corticosteroids,\n             medications for diarrhea-predominant irritable bowel syndrome, or Chinese herbal\n             medicine for the treatment of Crohn's disease (e.g., Daikenchuto)  within 13 days\n             before initiation of study drug administration 7. Patients  who have received\n             azathioprine, 6-mercaptopurine, or methotrexate within 27 days before initiation of\n             study drug administration. However, this shall not apply to patients who have\n             received these drugs for 83 or more days before initiation of the study drug\n             administration and continued the steady dose administration of the drugs for 27 or\n             more days before initiation of the study drug administration 8. Patients  who have\n             received cyclosporin, tacrolimus, tofacitinib or  any study drugs for treatment of\n             ulcerative colitis within 27 days before initiation of the study drug administration\n             9. Patients who have received adalimumab within 27 days before initiation of study\n             drug administration or any biological drugs other than adalimumab within 55 days\n             before initiation of study drug administration.Topical administration (such as\n             intraocular implantation for treatment of age-related maculopacy) is allowed 10.\n             Patients who have received any live vaccinations within 27 days before initiation of\n             study drug administration 11. Patients who have undergone intestinal resection within\n             27 days before initiation of study drug administration or those anticipated to\n             require intestinal resection during the study 12. Patients who have received\n             leukocytapheresis or granulocyte apheresis within 27 days before initiation of the\n             study drug administration 13. Patients who have received intravenous\n             hyperalimentation or total enteral nutrition within the 20 days before initiation of\n             the study drug administration. Or patients who are fasted 14. Patients who have\n             received enteral nutrition at > 900 kcal/day or started enteral nutrition at <= 900\n             kcal/day within the 20 days before initiation of the study drug administration.\n             Patients receiving 900 kcal/day or less of enteral nutrition for at least 21 days\n             before initiation of the study drug administration whom these dosage was changed or\n             the medications were discontinued within 20 days before initiation of the study drug\n             administration 15. Patients with evidence of adenomatous colonic polyps that need to\n             be removed at the start of study drug administration 16. Patients with a history or\n             an an complication of dysplasia of the small or large intestine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038920", 
            "org_study_id": "MLN0002/CCT-001", 
            "secondary_id": "U1111-1150-2688"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vedolizumab 300mg", 
                "description": "Vedolizumab intravenous injection", 
                "intervention_name": "Vedolizumab", 
                "intervention_type": "Drug", 
                "other_name": "MLN0002"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Vedolizumab placebo", 
                "intervention_name": "Vedolizumab placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan", 
                        "state": "Aichi"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toyota-shi", 
                        "country": "Japan", 
                        "state": "Aichi"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hirosaki-shi", 
                        "country": "Japan", 
                        "state": "Aomori"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakura-shi", 
                        "country": "Japan", 
                        "state": "Chiba"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukui-shi", 
                        "country": "Japan", 
                        "state": "Fukui"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chikushino-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitakyushu-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuyama-shi", 
                        "country": "Japan", 
                        "state": "Hiroshima"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hatsukaichi-shi", 
                        "country": "Japan", 
                        "state": "Hiroshima"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-shi", 
                        "country": "Japan", 
                        "state": "Hiroshima"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asahikawa-shi", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tomakomai-shi", 
                        "country": "Japan", 
                        "state": "Hokkaido"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akashi-shi", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nishinomiya-shi", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima-shi", 
                        "country": "Japan", 
                        "state": "Kagoshima"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sagamihara-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan", 
                        "state": "Kanagawa"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kochi-shi", 
                        "country": "Japan", 
                        "state": "Kochi"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto-shi", 
                        "country": "Japan", 
                        "state": "Kumamoto"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto-shi", 
                        "country": "Japan", 
                        "state": "Kyoto"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai-shi", 
                        "country": "Japan", 
                        "state": "Miyagi"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagasaki-shi", 
                        "country": "Japan", 
                        "state": "Nagasaki"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ohita-shi", 
                        "country": "Japan", 
                        "state": "Ohita"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moriguchi-shi", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-shi", 
                        "country": "Japan", 
                        "state": "Osaka"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saga-shi", 
                        "country": "Japan", 
                        "state": "Saga"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokorozawa-shi", 
                        "country": "Japan", 
                        "state": "Saitama"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu-shi", 
                        "country": "Japan", 
                        "state": "Shizuoka"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shimotsuke-shi", 
                        "country": "Japan", 
                        "state": "Tochigi"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adachi-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiyoda-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinagawa-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shunan-shi", 
                        "country": "Japan", 
                        "state": "Yamaguchi"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kofu-shi", 
                        "country": "Japan", 
                        "state": "Yamanashi"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+1-800-778-2860 (USA & EU)"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "General Manager", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of subjects randomized to the induction phase with a decrease from baseline of at least 100 points in the Crohn's Disease Activity Index (CDAI) score at Week 10CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.", 
                "measure": "Induction phase: Crohn's Disease Activity Index (CDAI)-100 response at Week 10", 
                "safety_issue": "No", 
                "time_frame": "At Week 10"
            }, 
            {
                "description": "Percentage of subjects randomized to the maintenance phase with clinical remission (Crohn's Disease Activity Index (CDAI) score \u2264150) at Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.", 
                "measure": "Maintenance Phase: Clinical remission at Week 60", 
                "safety_issue": "No", 
                "time_frame": "At Week 60"
            }, 
            {
                "description": "Tabulation of incidence of adverse events Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }, 
            {
                "description": "Summary statistics for body weight at each evaluation time point.", 
                "measure": "Body weight", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }, 
            {
                "description": "Summary statistics for vital signs at each evaluation time point.", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }, 
            {
                "description": "Summary statistics for Electrocardiogram (ECG) measurements at each evaluation time point.", 
                "measure": "Electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }, 
            {
                "description": "Summary statistics for measurements of clinical laboratory test at each evaluation time point.", 
                "measure": "Clinical laboratory test (bloodbiochemistry, hematology, and urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of subjects randomized to the induction phase with clinical remission (Crohn's Disease Activity Index (CDAI) score \u2264150) at Week 10 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.", 
                "measure": "Induction phase: Clinical remission at Week 10", 
                "safety_issue": "No", 
                "time_frame": "At Week 10"
            }, 
            {
                "description": "Summary statistics of C-reactive protein (CRP) values at each evaluation time point in the subpopulation of subjects randomized to the induction phase with a baseline CRP value exceeding 0.30 mg/dL", 
                "measure": "Induction phase:  Changes in C-reactive protein (CRP) values", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 10"
            }, 
            {
                "description": "Percentage of subjects randomized to the maintenance phase with a decrease from baseline of at least 100 points in the Crohn's Disease Activity Index (CDAI) score at Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.", 
                "measure": "Maintenance Phase: Crohn's Disease Activity Index (CDAI)-100 response at Week 60", 
                "safety_issue": "No", 
                "time_frame": "At Week 60"
            }, 
            {
                "description": "Percentage of subjects randomized to the maintenance phase with clinical remission (Crohn's Disease Activity Index (CDAI) score \u2264 150) at at least 80 percent of the scheduled visits, including Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.", 
                "measure": "Maintenance Phase: Durable clinical remission", 
                "safety_issue": "No", 
                "time_frame": "From Week 14 to Week 60"
            }, 
            {
                "description": "Percentage of subjects randomized to the maintenance phase who are not using the corticosteroids used at initiation of study drug administration and who show clinical remission (Crohn's Disease Activity Index (CDAI) score \u2264 150) at Week 60 CDAI is scoring system for the Assessment of Crohn's Disease Activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.", 
                "measure": "Maintenance Phase: Corticosteroid-free clinical remission at Week 60", 
                "safety_issue": "No", 
                "time_frame": "At Week 60"
            }, 
            {
                "description": "Summary statistics for serum  Vedolizumab concentration at each evaluation time point", 
                "measure": "Serum Vedolizumab concentration", 
                "safety_issue": "No", 
                "time_frame": "From Week 2 to Week 60"
            }, 
            {
                "description": "Tabulation of incidence of Human anti-human antibody (HAHA)", 
                "measure": "Human anti-human antibody(HAHA)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }, 
            {
                "description": "Tabulation of incidence of neutralizing antibody", 
                "measure": "Neutralizing antibody", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 16 weeks after the last dose of study drug"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}